ASH 2024 Summary: Highlights in CML

2024 ASH Annual Meeting Insights Hub

J. Yang

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASH 2024 Review: Practice-Changing Updates in the Management of CML

Cleveland Clinic Taussig Cancer Institute

A. Jain

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

AML, MDS, and CML Highlights & Key Takeaways From ASCO®/EHA 2024

Insights from 2024 EHA Annual Meeting

T. Badar

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

Fast Five Key Updates in Malignant Heme: Pearls From a Pharmacist

Total Health

S. Medeiros

Year in Review 2024: CML Highlights

Oncology 2024 Year in Review

J. Cortés

Critical Re-Evaluation of Established Practices in CML Management

XV Eurasian Hematology-Oncology Congress - EHOC 2024

H. Kantarjian

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

MRD Testing in Leukemias: When Negativity Is a Positive Thing

i3 Health

N. S. Raje

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

FDA Approved First Oral Solution of Imatinib

Winship Cancer Institute - Emory University

A. Abousaud

Efficacy and Safety of Asciminib in Ph+ CML

Luke Fletcher

ASH 2023 Insights: "Treatment Patterns & Clinical Outcomes Among Pat…

Insights from 2023 ASH Annual Meeting

E. Atallah

Current Treatment Landscape in Myeloid Malignancies

Houston Methodist

S. Shah

Highlights of ASH 2024: Key CML Oral Presentations

International CML Foundation

T. Hughes

Leukemia Tumor Board: Navigating Ambiguous Leukemia - CML-BP/MPAL

Tisch Cancer Institute at Mount Sinai

J. Anderson

Blood Cancers Basics

Masonic Cancer Center, University of Minnesota

Z. Sachs

Updates on Myeloproliferative Neoplasms Including CML

Winship Cancer Institute - Emory University

A. Hunter